Gratifying new treatment of advanced Urothelial Cancer
Best Practice Nordic | Jun 2019 | | ASCO
Locally advanced or metastatic urothelial cancer remains a lethal disease with limited treatment options for patients who progress on or after platinum and/or checkpoint inhibitor (CPI). In this MEDtalk Daniel Peter Petrylak present a new streatment of urothelial cancer Enfortumab vedotin (EV) - an antibody-drugconjugate targeting Nectin-4, which is highly expressed in UC. This study demonstrate the fact, that Enfortumab vedotin have a therapy that can help people who don’t benefit from checkpoint inhibitors.